discover THE
Capabilities OF Cue®
Discover Cue®: SynapCell's Predictive Translational In Vivo EEG Platform
An EEG trace alone cannot quantify the effect of a compound over time – it needs to be processed to reveal its full potential. In addition, to analyze and interpret EEGs requires a high level of training and expertise.
This is precisely why we have developed Cue®, our innovative predictive and translational in vivo EEG platform. Through its combination of high-level modeling methods, precise recording techniques, deep-learning-based signal processing and specific know-how, it guarantees exceptional and reliable results for your outsourced work.
Thanks to Cue®, we have developed a wide range of in vivo electrophysiology solutions, from off-the-shelf to tailor-made, to perfectly meet your needs in terms of efficacy testing, pharmaco-EEG, derisking, analysis of sleep and vigilance states, model exploration, etc. We also offer collaborative projects and can even act as your long-term outsourced preclinical EEG lab, to call on whenever you need our expertise.
EEG-based and inspired by clinical practice, Cue® combines the specific skills of SynapCell’s team in neuroscience and associated techniques, clinically relevant rodent models, and intelligent signal processing.
Your Asset to Inform Decision-Making in CNS Drug Discovery
Cue® is the result of decades of R&D, combining SynapCell’s know-how, expertise and scientific excellence in neuroscience – brain surgery, EEG signal recording, processing and analysis – and pharmacology.
Cue® is designed to reliably and objectively predict the clinical efficacy of your drug candidates right from the pre-clinical stage. Using Cue®, we transform pre-clinical data into actionable information for CNS drug discovery.
Our experienced staff conduct precise surgical interventions and implant electrodes for EEG recordings. We work with translational models, deploying high-level expertise in preclinical brain surgery to target various brain structures, and adhere to ethical guidelines.
Our primary expertise is in preclinical EEG recording and analysis for CNS disorders. We use advanced in vivo techniques, proprietary deep-learning platforms, and translational EEG biomarkers to provide precise, reproducible data, ensuring accurate assessment of drug efficacy and phenotyping of models.
Preclinical EEG analysis requires real expertise to account for signal complexity, model specificity, the need for astute interpretation (oscillatory changes may be minute but nevertheless significant), translation of knowledge from preclinical results to clinical observations, etc. SynapCell’s experts meet all these challenges, ensuring accurate data interpretation and reliable assessment of drug efficacy.
The name Cue® is derived from the letter “Q”, for Quantitative, but also reflects the similarities between music and EEG, more numerous than we might initially think. SynapCell’s core technology is capable of identifying specific electrical waves as cues (biomarkers) from neuronal networks, like musicians extracting the best samples from a song.
Dive into Cue®: Preclinical EEG Capabilities
quantitative
EEG
qEEG
Quantitative EEG (qEEG) is an advanced analysis of digital brainwave data using complex algorithms. It provides direct insight into brain function and connectivity for neurological assessment and treatment evaluation.
By placing electrodes at different depths in or on the brain, SynapCell uses quantitative EEG (qEEG) as a powerful translational tool for CNS drug discovery at the preclinical stage. qEEG results enhance the predictability of treatments for neurological conditions including Epilepsy and neurodegenerative, psychiatric, and rare disorders.
Seizure Detection
To obtain reliable results and analysis when detecting and quantifying epileptic seizures using EEG curves requires a high level of expertise.
SynapCell has defined EEG HPD/SWD as the most relevant biomarkers, developed advanced algorithms, unique know-how and expertise in preclinical EEG analysis to provide translational results. Using Fast Fourier Transforms (FFT), we can decompose the whole EEG spectrum to analyze the power of each frequency. On another level of analysis, we can zoom in on a specific band to study how its power changes over time and obtain high-quality advanced information and insights to aid decision-making. By mapping brainwave abnormalities in EEG signals, we identify patterns of brain activity indicative of epileptic seizures, thereby improving the accuracy of convulsive and non-convulsive seizure detection.
seizure
detection
auditory evoked
potentials
Auditory Evoked Potentials
Auditory Evoked Potentials (AEPs) are electrical signals generated by the nervous system in response to sound stimuli.
At SynapCell, these potentials are recorded using electrodes placed in the brains of rodents. At the preclinical stage, they have translational potential for the assessment of neurological disorders (e.g Schizophrenia, or more specifically, Cognitive Impairment Associated with Schizophrenia, CIAS) affecting auditory processing. These responses are also known to be perturbed in patients, and often reflect some degree of cognitive impairment.
Unleash the Power of Cue® for Preclinical Testing of CNS Drugs
Get further insights into the pharmacological mechanism of action and PK of your compound.
Characterize drug effects longitudnally over time and demonstrate (ir)reversibility, duration of effect, physiological target turn-over or target engagement.
Discover specific EEG biomarkers in translational models. Our in vivo EEG platform (Cue®) offers EEG, qEEG, ERP, seizure detection and characterization to identify EEG signatures of the disease or pharmacological pathway you are working on.
EEG Biomarkers have a high translational potential, as they are robust and objective measurements.
We can help you identify new EEG Biomarkers in the model of your choice, allowing you to stake your claim in the history of Science!
How does your drug compare with known mechanisms of action and/or the standard of care?
Assess the best possible drug combination (adjunctive therapies), demonstrate a superior effect, and evaluate your drug compared to reference drugs currently on the market.
The integration and processing of sensory information is altered in several neurological and psychiatric disorders.
Auditory evoked potentials (AERP) and the auditory steady state response (ASSR) can be used to assess the effect of drugs on cognitive function in vivo.
Select and validate the most effective among your drug compounds after screening.
Candidates with the most potential to lower pathological EEG signatures (EEG biomarkers) will be selected to proceed to dose-response testing, allowing you to select the most appropriate and effective dose.
If you can’t find what you need among our in vivo electrophysiology solutions, please contact us to explore a customized solution aligned with your requirements.
Let's Talk About Your Research Project!
More than a CRO, a team of collaborators – we are your dream neuroscience team specialized in preclinical EEG! We don’t just produce data, we are your partners from conceptualization to conclusion. We translate raw EEG data into meaningful, clinically-relevant endpoints, delivering clear insights to allow data-based decision-making. Choose SynapCell, a leading preclinical CNS-specialized CRO for cutting-edge EEG expertise combined with an irresistible touch of fun.
News & Events